Jose M. Puerta

Granada, AN, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Correction to: Validation of the Spanish version of the EORTC QLQ-CML24 questionnaire for assessment of health-related quality of life in patients with chronic myeloid leukemia.

Correction to: Validation of the Spanish version of the EORTC QLQ-CML24 questionnaire for assessment of health-related quality of life in patients with chronic myeloid leukemia.

Journal: Annals of hematology

Published: September 05, 2025

Validation of the Spanish version of the EORTC QLQ-CML24 questionnaire for assessment of health-related quality of life in patients with chronic myeloid leukemia.

Validation of the Spanish version of the EORTC QLQ-CML24 questionnaire for assessment of health-related quality of life in patients with chronic myeloid leukemia.

Journal: Annals of hematology

Published: April 30, 2025

Data Model for the Comprehensive Management of Biobanks and Its Contribution to Personalized Medicine.

Data Model for the Comprehensive Management of Biobanks and Its Contribution to Personalized Medicine.

Journal: Journal of personalized medicine

Published: April 25, 2024

Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era.

Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era.

Journal: Pharmaceutics

Published: October 16, 2023

Concentration of low-density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation.

Concentration of low-density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation.

Journal: Scientific reports

Published: January 30, 2023

A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia.

A Real-World Evidence-Based Study of Long-Term Tyrosine Kinase Inhibitors Dose Reduction or Discontinuation in Patients with Chronic Myeloid Leukaemia.

Journal: Pharmaceutics

Published: January 14, 2023

Venetoclax for treating refractory autoimmune hemolytic anemia in chronic lymphocytic leukemia: report of two cases in Spain.

Venetoclax for treating refractory autoimmune hemolytic anemia in chronic lymphocytic leukemia: report of two cases in Spain.

Journal: Haematologica

Published: September 24, 2022

Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia.

Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia.

Journal: Journal of personalized medicine

Published: August 10, 2022

Influence of the ectopic location on the antigen expression and functional characteristics of endometrioma stromal cells.

Influence of the ectopic location on the antigen expression and functional characteristics of endometrioma stromal cells.

Journal: Reproductive biomedicine online

Published: July 29, 2022

Arterial hypertension assessment in a population with chronic myeloid leukemia.

Arterial hypertension assessment in a population with chronic myeloid leukemia.

Journal: Scientific reports

Published: April 19, 2021

Progressive cardiovascular disease in a patient under treatment with nilotinib.

Progressive cardiovascular disease in a patient under treatment with nilotinib.

Journal: Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis

Published: May 20, 2019

Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.

Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.

Journal: Blood cancer journal

Published: July 17, 2018

Showing 1-12 of 20

Last Updated: 09/26/2026